TY - JOUR
T1 - Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects
AU - Sørensen, Nina Vindegaard
AU - Nilsson, Anna Christine
AU - Orlovska-Waast, Sonja
AU - Jeppesen, Rose
AU - Christensen, Rune Haubo Bojesen
AU - Benros, Michael Eriksen
N1 - © 2023 Published by Elsevier Inc on behalf of Society of Biological Psychiatry.
PY - 2023/10
Y1 - 2023/10
N2 - No large studies have investigated the prevalence of cerebrospinal fluid antineuronal autoantibodies in isolated depression. In this case-control study comparing 106 patients with isolated depression (ICD-10 code F32) with 106 healthy control subjects, cerebrospinal fluid and serum samples were tested for 7 immunoglobulin G autoantibodies using commercial fixed cell-based assays. To explore validity of methods, positive samples were retested twice by cell-based assays and once by tissue-based assays (monkey cerebellum). The prevalence of any of the antineuronal autoantibodies in cerebrospinal fluid was 0.0% in both groups and the seroprevalence was 0.9% in both groups, based on consistent findings in cell-based assays. However, all samples were negative by the tissue-based assay. Evaluation of antineuronal autoantibodies in cerebrospinal fluid cannot be recommended routinely for patients with isolated depression of moderate severity. Future studies of isolated depression should consider much larger sample sizes and evaluation of antineuronal autoantibodies using modalities other than commercial kits.
AB - No large studies have investigated the prevalence of cerebrospinal fluid antineuronal autoantibodies in isolated depression. In this case-control study comparing 106 patients with isolated depression (ICD-10 code F32) with 106 healthy control subjects, cerebrospinal fluid and serum samples were tested for 7 immunoglobulin G autoantibodies using commercial fixed cell-based assays. To explore validity of methods, positive samples were retested twice by cell-based assays and once by tissue-based assays (monkey cerebellum). The prevalence of any of the antineuronal autoantibodies in cerebrospinal fluid was 0.0% in both groups and the seroprevalence was 0.9% in both groups, based on consistent findings in cell-based assays. However, all samples were negative by the tissue-based assay. Evaluation of antineuronal autoantibodies in cerebrospinal fluid cannot be recommended routinely for patients with isolated depression of moderate severity. Future studies of isolated depression should consider much larger sample sizes and evaluation of antineuronal autoantibodies using modalities other than commercial kits.
KW - Autoantibodies
KW - Autoimmune encephalitis
KW - Biomarkers
KW - Cerebrospinal fluid
KW - Depression
KW - Immunology
UR - http://www.scopus.com/inward/record.url?scp=85149639038&partnerID=8YFLogxK
U2 - 10.1016/j.bpsgos.2022.10.007
DO - 10.1016/j.bpsgos.2022.10.007
M3 - Journal article
C2 - 37881586
SN - 2667-1743
VL - 3
SP - 1116
EP - 1121
JO - Biological psychiatry global open science
JF - Biological psychiatry global open science
IS - 4
ER -